WO2014035140A3 - Compounds and compositions for modulating histone methyltransferase activity - Google Patents

Compounds and compositions for modulating histone methyltransferase activity Download PDF

Info

Publication number
WO2014035140A3
WO2014035140A3 PCT/KR2013/007728 KR2013007728W WO2014035140A3 WO 2014035140 A3 WO2014035140 A3 WO 2014035140A3 KR 2013007728 W KR2013007728 W KR 2013007728W WO 2014035140 A3 WO2014035140 A3 WO 2014035140A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
compositions
methyltransferase activity
histone methyltransferase
modulating histone
Prior art date
Application number
PCT/KR2013/007728
Other languages
French (fr)
Other versions
WO2014035140A2 (en
Inventor
Jae Moon Lee
MinJeong CHOI
Original Assignee
Kainos Medicine, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kainos Medicine, Inc. filed Critical Kainos Medicine, Inc.
Publication of WO2014035140A2 publication Critical patent/WO2014035140A2/en
Publication of WO2014035140A3 publication Critical patent/WO2014035140A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides DOT1L inhibitors, and also methods and use of the compounds of the invention, by themselves or in combination with other therapies, for treating a disease, disorder, or condition.
PCT/KR2013/007728 2012-08-30 2013-08-28 Compounds and compositions for modulating histone methyltransferase activity WO2014035140A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261694892P 2012-08-30 2012-08-30
US61/694,892 2012-08-30

Publications (2)

Publication Number Publication Date
WO2014035140A2 WO2014035140A2 (en) 2014-03-06
WO2014035140A3 true WO2014035140A3 (en) 2014-05-01

Family

ID=50184543

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2013/007728 WO2014035140A2 (en) 2012-08-30 2013-08-28 Compounds and compositions for modulating histone methyltransferase activity

Country Status (1)

Country Link
WO (1) WO2014035140A2 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2723746A1 (en) 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
WO2014039839A1 (en) 2012-09-06 2014-03-13 Epizyme, Inc. Method of treating leukemia
CN107501275B (en) 2012-12-07 2019-11-22 沃泰克斯药物股份有限公司 It can be used as the compound of ATR kinase inhibitor
US9446064B2 (en) 2013-03-14 2016-09-20 Epizyme, Inc. Combination therapy for treating cancer
EP2970289A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
WO2014143242A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2970286A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
RU2720408C2 (en) 2013-12-06 2020-04-29 Вертекс Фармасьютикалз Инкорпорейтед Method of producing atr kinase inhibitors (embodiments)
AU2015271030B2 (en) 2014-06-05 2019-05-16 Vertex Pharmaceuticals Incorporated Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo [1,5-a] pyrimidin-3-carboxamide compound useful as ATR kinase inhibitor, the preparation of said compound and different solid forms thereof
ES2733847T3 (en) 2014-06-17 2019-12-03 Vertex Pharma Method to treat cancer using a combination of CHK1 and ATR inhibitors
TWI730980B (en) 2015-08-26 2021-06-21 比利時商健生藥品公司 Novel 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as prmt5 inhibitors
WO2017059357A1 (en) 2015-09-30 2017-04-06 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of dna damaging agents and atr inhibitors
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
UA123637C2 (en) 2016-03-10 2021-05-05 Янссен Фармацевтика Нв Substituted nucleoside analogues for use as prmt5 inhibitors
SI3436461T1 (en) 2016-03-28 2024-03-29 Incyte Corporation Pyrrolotriazine compounds as tam inhibitors
EP3512858B1 (en) 2016-09-14 2023-11-08 Janssen Pharmaceutica NV Fused bicyclic inhibitors of menin-mll interaction
KR102493644B1 (en) 2016-09-14 2023-01-30 얀센 파마슈티카 엔.브이. Spiro bicyclic inhibitor of the menin-MLL interaction
WO2018065365A1 (en) 2016-10-03 2018-04-12 Janssen Pharmaceutica Nv Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
CA3037998A1 (en) 2016-10-03 2018-04-12 Janssen Pharmaceutica Nv Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
KR102513564B1 (en) 2016-12-15 2023-03-22 얀센 파마슈티카 엔.브이. An azepane inhibitor of the menin-MLL interaction
MX2019010150A (en) 2017-02-27 2019-10-21 Janssen Pharmaceutica Nv Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor.
CN109748921B (en) * 2017-11-03 2022-03-22 中国科学院上海药物研究所 N-tert-butyloxycarbonyl protected heterocyclic compound, preparation method thereof and method for preparing C-nucleoside analogue by using N-tert-butyloxycarbonyl protected heterocyclic compound
JP7352544B2 (en) 2017-12-08 2023-09-28 ヤンセン ファーマシューティカ エヌ．ベー． Novel spirobicyclic analogs
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
AU2020218872A1 (en) * 2019-02-07 2021-08-26 Beigene, Ltd. Imidazo (2, 1-f) (1, 2, 4) triazin-4-amine derivatives as TLR7 agonist
TW202112375A (en) 2019-06-06 2021-04-01 比利時商健生藥品公司 Methods of treating cancer using prmt5 inhibitors
CR20220012A (en) 2019-06-12 2022-03-11 Janssen Pharmaceutica Nv NEW SPIROBICYCLIC INTERMEDIATES
TWI794742B (en) 2020-02-18 2023-03-01 美商基利科學股份有限公司 Antiviral compounds
CN111484537B (en) * 2020-05-19 2021-10-01 南京工业大学 Method for preparing Rudesiwei key intermediate by using microchannel reaction device
CN111793101B (en) 2020-07-17 2022-09-30 四川大学 Process for the synthesis of C-nucleoside compounds
US11697666B2 (en) 2021-04-16 2023-07-11 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
PE20240654A1 (en) 2021-08-20 2024-04-04 Shionogi & Co NUCLEOSIDE DERIVATIVES AND PRODRUGS THEREOF THAT HAVE INHIBITORY ACTION OF VIRAL GROWTH

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009132135A1 (en) * 2008-04-23 2009-10-29 Gilead Sciences, Inc. 1' -substituted carba-nucleoside analogs for antiviral treatment
WO2011035250A1 (en) * 2009-09-21 2011-03-24 Gilead Sciences, Inc. Processes and intermediates for the preparation of 1'-substituted carba-nucleoside analogs
WO2012012776A1 (en) * 2010-07-22 2012-01-26 Gilead Sciences, Inc. Methods and compounds for treating paramyxoviridae virus infections

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009132135A1 (en) * 2008-04-23 2009-10-29 Gilead Sciences, Inc. 1' -substituted carba-nucleoside analogs for antiviral treatment
WO2009132123A1 (en) * 2008-04-23 2009-10-29 Gilead Sciences, Inc. Carba-nucleoside analogs for antiviral treatment
WO2011035250A1 (en) * 2009-09-21 2011-03-24 Gilead Sciences, Inc. Processes and intermediates for the preparation of 1'-substituted carba-nucleoside analogs
WO2012012776A1 (en) * 2010-07-22 2012-01-26 Gilead Sciences, Inc. Methods and compounds for treating paramyxoviridae virus infections

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SAMMY E. METOBO ET AL.: "Practical synthesis of l' -substituted Tubercidin C-nucleoside analogs", TETRAHEDRON LETTERS, vol. 53, 2012, pages 484 - 486 *

Also Published As

Publication number Publication date
WO2014035140A2 (en) 2014-03-06

Similar Documents

Publication Publication Date Title
WO2014035140A3 (en) Compounds and compositions for modulating histone methyltransferase activity
WO2014042433A3 (en) Compounds and compositions for modulating adenosine a3 receptor activity
PH12014502704A1 (en) Compounds and compositions for modulating egfr activity
EP2919681A4 (en) Minimally invasive devices, systems and methods for treating the spine
WO2012082436A3 (en) Modulators of histone methyltransferase, and methods of use thereof
IL245062A0 (en) 1 -(5-tert-butyl-2-aryl-pyrazol-3-yl)-3-[2-fluoro-4-[(3-oxo-4h-pyrido[2, 3-b]pyrazin-8-yl)oxy]phenyl]urea derivatives as raf inhibitors for the treatment of cancer
EP2914186A4 (en) Systems and methods for creating curved paths through bone and modulating nerves within the bone
GB2502881B (en) Systems, devices, and/or methods for managing implantable devices
EP3054954A4 (en) Hdac inhibitors, alone or in combination with btk inhibitors, for treating non-hodgkin's lymphoma
WO2012062925A3 (en) Compounds and methods for treating pain
EP3054953A4 (en) Hdac inhibitors, alone or in combination with pi3k inhibitors, for treating non-hodgkin's lymphoma
EP3043825A4 (en) Gene therapy for the regeneration of chondrocytes or cartilage type cells
PH12014501653A1 (en) Metalloenzyme inhibitor compounds
EP2836271A4 (en) Devices, systems and methods for modulation of the nervous system
EP2724309A4 (en) Social match platform apparatuses, methods and systems
EP2528893A4 (en) Small molecules for the modulation of mcl-1 and methods of modulatiing cell death, cell division, cell differentiation and methods of treating disorders
WO2012116237A3 (en) Heterocyclic compounds and uses thereof
BR112015007061A2 (en) compound, pharmaceutical composition and method for treating an apkc-dependent condition or disorder in a patient
SG11201502713QA (en) Compositions, structures and methods for neural regeneration
WO2013177535A8 (en) Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta
BR112013015901A2 (en) insert, and method for introducing aroma, or increasing the applied aroma level, into one or more smoking articles
EP2780341A4 (en) Kinase modulating compounds, compositions containing the same and use thereof
WO2012158672A3 (en) Compounds for use in treatment of mucositis
CA2875305C (en) Fbxo3 inhibitors
EP3079680A4 (en) Compositions and methods for treating, preventing and diagnosing cancer and other proliferative disorders

Legal Events

Date Code Title Description
32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205 DATED 03.07.2015)

122 Ep: pct application non-entry in european phase

Ref document number: 13833601

Country of ref document: EP

Kind code of ref document: A2